XLMTM may require immediate respiratory support at birth

XLMTM is a life-threatening disease

Patients with X-linked myotubular myopathy (XLMTM) typically present at birth with profound muscle weakness, hypotonia, and respiratory distress.1-3 Symptoms range in severity, and the majority of patients require immediate intervention, such as invasive ventilatory support and gastrostomy tube feeding.4 Patients continue to face life-threatening symptoms and substantial challenges throughout their lives.

Morbidity and mortality

XLMTM is characterized by high rates of morbidity and mortality, which can significantly impact patient and caregiver quality of life and place a substantial burden on the healthcare system.1,5,6

Approximately 50% of patients with XLMTM die in the first 18 months of life due to respiratory failure or related complications (eg, pneumonia, respiratory tract infections, or ventilator-related accidents).2,5

Patients who survive infancy often require daily intensive medical intervention with up to 24 hours of invasive mechanical ventilation and gastrostomy tube feeding.1,2,5

The majority of these patients are not ambulatory, never achieving normal motor milestones, such as head control, sitting, standing, or walking.5-7

Respiratory Implications

Learn how respiratory insufficiency impacts patients living with XLMTM.


1. Beggs AH, et al. Muscle Nerve. 2018;57(4):550-560. 2. Graham RJ, et al. Arch Dis Child. 2020;105(4):332-338. 3. North KN, et al. Neuromuscul Disord. 2014;24(2):97-116. 4. Dowling JJ, et al. In: Adam MP, et al, eds. GeneReviews®. 2002. 5. McEntagart M, et al. Neuromuscul Disord. 2002;12(10):939-946. 6. Amburgey K, et al. Neurology. 2017;89(13):1355-1364. 7. Annoussamy M, et al. Neurology. 2019;92(16):e1852-e1867.


Connect with us to get the latest information

Email Address*
Phone Number
Institution / Affiliation*

*Required fields

By submitting this form, you agree to allow Astellas Gene Therapies and its agents to collect the information provided and to be contacted directly by an Astellas Gene Therapies representative. Your information will not be used for any other purpose than for a representative to respond to your information request and/or to send you XLMTM updates if you have registered to receive them.

Astellas Gene Therapies will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Astellas Gene Therapies and its agents. Astellas Gene Therapies will only use your information in accordance with its Privacy Statement.